With Ultrasound on a Chip, Butterfly Network Aims for Global Reach

Why It Matters

Low‑cost, AI‑enabled ultrasound could democratize diagnostic imaging for underserved populations and expand Butterfly’s addressable market, while its financial results highlight the scaling challenges of med‑tech hardware firms.

Key Takeaways

• Butterfly's handheld ultrasound sells for about $4,000, far below $30k carts.
• Over 150,000 devices deployed globally, including Kenya and the ISS.
• AI partnership with Midjourney adds $15M upfront and $10M yearly fees.
• 2023 revenue $97.6M, but net loss $77.1M highlights growth costs.

Pulse Analysis

The global shortage of diagnostic imaging—two‑thirds of the world’s population lacks access—has created a fertile market for point‑of‑care ultrasound. Butterfly Network’s chip‑based probe, housing 9,000 micro‑sensors, delivers both high‑frequency surface imaging and deeper scans from a single handheld unit that plugs into a smartphone. By pricing the system at roughly $4,000, it undercuts traditional cart‑based machines that can exceed $200,000, opening doors for rural clinics, emergency responders, and even space missions to obtain real‑time imaging without a dedicated radiology suite.

Artificial intelligence is the next lever of differentiation. Butterfly’s recent licensing deal with generative‑AI firm Midjourney, valued at $15 million upfront plus $10 million annually, signals a push to embed sophisticated image‑analysis tools directly into the device. FDA clearance for an AI gestational‑age estimator and third‑party heart‑scan applications further lower the expertise barrier, allowing clinicians—or potentially patients—to capture diagnostic‑quality scans with minimal training. Competitors such as GE’s Vscan Air and Philips’ Lumify offer similar hardware, but Butterfly’s integrated AI ecosystem could accelerate adoption among non‑specialist users.

Financially, the company posted $97.6 million in revenue last year but recorded a $77.1 million net loss, reflecting heavy R&D spend and the costs of scaling a hardware‑centric business. Its market capitalization slipped to $1.37 billion, half of its IPO valuation, underscoring investor caution. Nevertheless, the firm’s strategy to expand AI capabilities, explore new form factors like patches or endoscopic modules, and deepen distribution in emerging markets positions it for long‑term growth. Success will hinge on converting the large installed base into recurring subscription revenue and achieving broader regulatory approvals, which could ultimately reshape the economics of medical imaging.